KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Change in Inventory (2017 - 2025)

Bionano Genomics' Change in Inventory history spans 7 years, with the latest figure at -$1.5 million for Q3 2025.

  • For Q3 2025, Change in Inventory fell 161.6% year-over-year to -$1.5 million; the TTM value through Sep 2025 reached -$6.3 million, down 262.93%, while the annual FY2024 figure was $587000.0, 85.86% down from the prior year.
  • Change in Inventory for Q3 2025 was -$1.5 million at Bionano Genomics, down from -$724000.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $6.7 million in Q3 2021 and bottomed at -$3.5 million in Q3 2023.
  • The 5-year median for Change in Inventory is $1.6 million (2023), against an average of $2.2 million.
  • The largest annual shift saw Change in Inventory surged 847.71% in 2021 before it plummeted 986.4% in 2024.
  • A 5-year view of Change in Inventory shows it stood at $5.6 million in 2021, then decreased by 0.48% to $5.6 million in 2022, then crashed by 94.04% to $331000.0 in 2023, then tumbled by 986.4% to -$2.9 million in 2024, then soared by 48.6% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Change in Inventory are -$1.5 million (Q3 2025), -$724000.0 (Q2 2025), and -$1.1 million (Q1 2025).